CXCL9



CXCL9

T1TT1P2PP2V3VV3V4VV4R5RR5K6KK6G7GG7R8RR8C9CC9S10SS10C11CC11I12II12S13SS13T14TT14N15NN15Q16QQ16G17GG17T18TT18I19II19H20HH20L21LL21Q22QQ22S23SS23L24LL24K25KK25D26DD26L27LL27K28KK28Q29QQ29F30FF30A31AA31P32PP32S33SS33P34PP34S35SS35C36CC36E37EE37K38KK38I39II39E40EE40I41II41I42II42A43AA43T44TT44L45LL45K46KK46N47NN47... and 56 more residue(s)...... and 56 more residue(s)

SMILES None
InChIKey None
Sequence TPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQKKKQKNGKKHQKKKVLKVRKSQRSRQKKTT

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

CXCL9

T1TT1P2PP2V3VV3V4VV4R5RR5K6KK6G7GG7R8RR8C9CC9S10SS10C11CC11I12II12S13SS13T14TT14N15NN15Q16QQ16G17GG17T18TT18I19II19H20HH20L21LL21Q22QQ22S23SS23L24LL24K25KK25D26DD26L27LL27K28KK28Q29QQ29F30FF30A31AA31P32PP32S33SS33P34PP34S35SS35C36CC36E37EE37K38KK38I39II39E40EE40I41II41I42II42A43AA43T44TT44L45LL45K46KK46N47NN47... and 56 more residue(s)...... and 56 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.